PROVIDENCE, R.I.--(BUSINESS WIRE)--EpiVax, Inc, a leader the field of second generation protein therapeutics, announced today that it has received a grant to reengineer Factor VIII (FVIII), the primary therapeutic used to control bleeding for individuals who have acquired or hereditary hemophilia.
